Pharmasset (Nasdaq:VRUS) Pipeline Still in Early Stages

Filed in baird, earnings, Gold Bullion prices, o, Pharmasset, shares by on November 26, 2010 0 Comments

Baird said they continue to recommend shares of Pharmasset (Nasdaq:VRUS), although it must be understood they they’re still in the early stage of developing their pipeline.Baird said, “Continue to recommend purchase on confirmatory FQ4-10 update. There were a few bits of incremental progress, in line with expectations and likely not stock-moving. We view Phase 2 data rollout as the best

Continue Reading »